Activity in Nodose Ganglia Neurons After Treatment with CP 55,940 and Cholecystokinin

Overview

Journal Physiol Rep

Specialty Physiology

Date 2018 Dec 5

PMID 30512249

Citations 3

Authors

Juliane R Johnston

Kimberly G Freeman

Gaylen L Edwards

Affiliations

Soon will be listed here.

Abstract

Previous work has shown that cannabinoids increase feeding, while cholecystokinin (CCK) has an anorexigenic effect on food intake. Receptors for these hormones are located on cell bodies of vagal afferent nerves in the nodose ganglia. An interaction between CCK and endocannabinoid receptors has been suggested. The purpose of these studies is to explore the effect of pretreatment with a cannabinoid agonist, CP 55,940, on nodose neuron activation by CCK. To determine the effect of CP 55,940 and CCK on neuron activation, rats were anesthetized and nodose ganglia were excised. The neurons were dissociated and placed in culture on coverslips. The cells were treated with media; CP 55,940; CCK; CP 55,940 followed by CCK; or AM 251, a CB1 receptor antagonist, and CP 55,940 followed by CCK. Immunohistochemistry was performed to stain the cells for cFos as a measure of cell activation. Neurons were identified using neurofilament immunoreactivity. The neurons on each slip were counted using fluorescence imaging, and the number of neurons that were cFos positive was counted in order to calculate the percentage of activated neurons per coverslip. Pretreatment with CP 55,940 decreased the percentage of neurons expressing cFos-immunoreactivity in response to CCK. This observation suggests that cannabinoids inhibit CCK activation of nodose ganglion neurons.

Citing Articles

Non-neuronal crosstalk promotes an inflammatory response in nodose ganglia cultures after exposure to byproducts from gram positive, high-fat-diet-associated gut bacteria.

Cawthon C, Kirkland R, Pandya S, Brinson N, de La Serre C Physiol Behav. 2020; 226:113124.

PMID: 32763334 PMC: 7530053. DOI: 10.1016/j.physbeh.2020.113124.

Gastrointestinal dysfunction after spinal cord injury.

Holmes G, Blanke E Exp Neurol. 2019; 320:113009.

PMID: 31299180 PMC: 6716787. DOI: 10.1016/j.expneurol.2019.113009.

Activity in nodose ganglia neurons after treatment with CP 55,940 and cholecystokinin.

Johnston J, Freeman K, Edwards G Physiol Rep. 2018; 6(23):e13927.

PMID: 30512249 PMC: 6278814. DOI: 10.14814/phy2.13927.

References

Cluny N, Keenan C, Reimer R, Le Foll B, Sharkey K . Prevention of Diet-Induced Obesity Effects on Body Weight and Gut Microbiota in Mice Treated Chronically with Δ9-Tetrahydrocannabinol. PLoS One. 2015; 10(12):e0144270. PMC: 4669115. DOI: 10.1371/journal.pone.0144270. View

Andresen M, Peters J . Comparison of baroreceptive to other afferent synaptic transmission to the medial solitary tract nucleus. Am J Physiol Heart Circ Physiol. 2008; 295(5):H2032-42. PMC: 2614577. DOI: 10.1152/ajpheart.00568.2008. View

Gibbs J, Young R, Smith G . Cholecystokinin elicits satiety in rats with open gastric fistulas. Nature. 1973; 245(5424):323-5. DOI: 10.1038/245323a0. View

Pertwee R . Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. Curr Med Chem. 2010; 17(14):1360-81. PMC: 3013229. DOI: 10.2174/092986710790980050. View

Muccioli G, Naslain D, Backhed F, Reigstad C, Lambert D, Delzenne N . The endocannabinoid system links gut microbiota to adipogenesis. Mol Syst Biol. 2010; 6:392. PMC: 2925525. DOI: 10.1038/msb.2010.46. View

Berthoud H, Neuhuber W . Functional and chemical anatomy of the afferent vagal system. Auton Neurosci. 2001; 85(1-3):1-17. DOI: 10.1016/S1566-0702(00)00215-0. View

Herkenham M, Lynn A, Johnson M, Melvin L, De Costa B, Rice K . Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci. 1991; 11(2):563-83. PMC: 6575215. View

Cummings D, Overduin J . Gastrointestinal regulation of food intake. J Clin Invest. 2007; 117(1):13-23. PMC: 1716217. DOI: 10.1172/JCI30227. View

Herkenham M, Groen B, Lynn A, De Costa B, Richfield E . Neuronal localization of cannabinoid receptors and second messengers in mutant mouse cerebellum. Brain Res. 1991; 552(2):301-10. DOI: 10.1016/0006-8993(91)90096-e. View

10.

Rehfeld J . Cholecystokinin as satiety signal. Int J Obes. 1981; 5(5):465-9. View

11.

Andrews P, Sanger G . Abdominal vagal afferent neurones: an important target for the treatment of gastrointestinal dysfunction. Curr Opin Pharmacol. 2002; 2(6):650-6. DOI: 10.1016/s1471-4892(02)00227-8. View

12.

de Lartigue G, Barbier de La Serre C, Raybould H . Vagal afferent neurons in high fat diet-induced obesity; intestinal microflora, gut inflammation and cholecystokinin. Physiol Behav. 2011; 105(1):100-5. PMC: 3156356. DOI: 10.1016/j.physbeh.2011.02.040. View

13.

Engel M, Kellermann C, Burnat G, Hahn E, Rau T, Konturek P . Mice lacking cannabinoid CB1-, CB2-receptors or both receptors show increased susceptibility to trinitrobenzene sulfonic acid (TNBS)-induced colitis. J Physiol Pharmacol. 2010; 61(1):89-97. View

14.

Travagli R, Hermann G, Browning K, Rogers R . Brainstem circuits regulating gastric function. Annu Rev Physiol. 2006; 68:279-305. PMC: 3062484. DOI: 10.1146/annurev.physiol.68.040504.094635. View

15.

Hamilton M, Raybould H . Bugs, guts and brains, and the regulation of food intake and body weight. Int J Obes Suppl. 2017; 6(Suppl 1):S8-S14. PMC: 5485880. DOI: 10.1038/ijosup.2016.3. View

16.

Cluny N, Baraboi E, Mackie K, Burdyga G, Richard D, Dockray G . High fat diet and body weight have different effects on cannabinoid CB(1) receptor expression in rat nodose ganglia. Auton Neurosci. 2013; 179(1-2):122-30. PMC: 3866822. DOI: 10.1016/j.autneu.2013.09.015. View

17.

Matsuda L, Bonner T, Lolait S . Localization of cannabinoid receptor mRNA in rat brain. J Comp Neurol. 1993; 327(4):535-50. DOI: 10.1002/cne.903270406. View

18.

Simasko S, Wiens J, Karpiel A, Covasa M, Ritter R . Cholecystokinin increases cytosolic calcium in a subpopulation of cultured vagal afferent neurons. Am J Physiol Regul Integr Comp Physiol. 2002; 283(6):R1303-13. DOI: 10.1152/ajpregu.00050.2002. View

19.

TSOU K, Brown S, Mackie K, Walker J . Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience. 1998; 83(2):393-411. DOI: 10.1016/s0306-4522(97)00436-3. View

20.

Burdyga G, Varro A, Dimaline R, Thompson D, Dockray G . Expression of cannabinoid CB1 receptors by vagal afferent neurons: kinetics and role in influencing neurochemical phenotype. Am J Physiol Gastrointest Liver Physiol. 2010; 299(1):G63-9. PMC: 2904113. DOI: 10.1152/ajpgi.00059.2010. View